The state of cancer care in Russia: malignant tumors of the skin (C44). One- and five-years survival of patients, age characteristics. Part II

Cover Page

Cite item

Full Text

Abstract

Pancreas cancer (С25) is a cancer with an unfavorable prognosis, remains one of the most lethal types of cancer, at the national level mortality exceeds morbidity. The analysis of patient survival at the population level on the scale of federal districts is not carried out in Russia with the exception of the North-West Federal District. Considering that the levels of standardized rates of morbidity and mortality from pancreas cancer are close in Russia and NWFD, and the value of index of accuracy practically coincide, the results of the population cancer registry (PCR) of the NWFD RF actually characterize the state of cancer care on average in Russia, with the exception of autonomous districts. The aim of the second stage of the study was to identify the true state of the effectiveness of the oncological service in Russia by calculating a key parameter – evaluating its performance, specifically, calculating the leading parameter – the survival rate of patients, taking into account the stage, localization, histological structure, and the possibility of curing patients The conducted research made it possible to determine the effectiveness of providing specialized oncological care to patients with pancreas cancer at the federal district level. An increase in the one–year observed survival rate for the period from 2000 to 2004 to 2015-2019 was established from 16.0 to 21.8% or by 36.3%, and five–year from 5.1 to 6.0%. The median survival rate did not reach 4 years. A significant difference in the levels of one-year survival of patients in different age groups has been established. Significant defects in the distribution of patients according to the stage of the disease were revealed. The specification of patient survival by detailed localization groups and major histotypes of tumors was studied.

About the authors

Vakhtang M. Merabishvili

N. N. Petrov National Medical Research Centre of Oncology Ministry of public health of Russian Federation

Author for correspondence.
Email: MVM@niioncologii.ru

Honored Scientist of the Russian Federation, Dr.Med.Sci., Professor, Head of the Department of Cancer Statistics, N. N. Petrov National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; Chairman of the Scientific and Medical Council for the Development of Information Systems of the Oncological Service of the Northwestern Region of Russia; Head of the Population Cancer Registry of the Northwestern Federal District of the Russian Federation

Russian Federation, Saint Petersburg

Lev V. Demidov

Blokhin National Medical Research Center of Oncology of the Russian Ministry

Email: info@ronc.ru

Dr. Med.Sci., Professor, Head of the Department of Skin Tumors of the Department of Drug Treatment, Blokhin National Medical Research Center of Oncology of the Russian Ministry

Russian Federation, Moscow

Alexey M. Belyaev

N. N. Petrov National Medical Research Centre of Oncology Ministry of public health of Russian Federation; North-Western State Medical University named after I.I. Mechnikov

Email: bam281060@yandex.ru

Dr. Med.Sci., Professor, Honored Doctor of the Russian Federation, Corresponding Member of RAS, Director of the N. N. Petrov National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; Head of the Department of Oncology, North-Western State Medical University named after I.I. Mechnikov

Russian Federation, Saint Petersburg; Saint Petersburg

Georgy I. Gafton

N. N. Petrov National Medical Research Centre of Oncology Ministry of public health of Russian Federation

Email: center.petrova@niioncologii.ru

Dr. Med.Sci., Head of the Scientific Department of General Oncology and Urology, N. N. Petrov National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Russian Federation, Saint Petersburg

Igor V. Samoilenko

Blokhin National Medical Research Center of Oncology of the Russian Ministry

Email: info@ronc.ru

MD, PhD, Senior Researcher, Department of Skin Tumors, Department of Drug Treatment, Blokhin National Medical Research Center of Oncology of the Russian Ministry

Russian Federation, Moscow

Vladimir V. Perelygin

Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation

Email: vladimir.pereligin@pharminnotech.com

Dr. Med. Sci., Professor, Honored Doctor of the Russian Federation, Head of the Industrial Ecology Department, Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation

Russian Federation, Saint Petersburg

References

  1. Berrino F., Sant M., Verdecchia V., Capocaccia R., Hakulinen T., Estéve J., eds. Survival of cancer patients in Europe: the EUROCARE Study (IARC Scientific Publications No. 132). Lyon: International Agency for Research on Cancer, 1995.
  2. Berrino F., Capocaccia R., Coleman M. P., Esteve J., Gatta G., Hakulinen T., Micheli M., Sant M., Verdecchia V., eds. Survival of cancer patients in Europe: the EUROCARE-2 study (IARC Scientific Publications No. 151). Lyon: International Agency for Research on Cancer, 1999.
  3. Berrino F., Capocaccia R., Esteve J., Gatta G., Hakulinen T., Micheli M., Sant M., Verdecchia V., eds. EUROCARE-3: the survival of cancer patients diagnosed in Europe during 1990–94. Ann Oncol 2003; 14 (Suppl. 5):pp1–155
  4. Capocaccia R., Gavin A., Hakulinen T., Lutz J. M., Sant M. (eds.) Survival of cancer patients in Europe, 1995–2002. The EUROCARE-4 study. Eur J Cancer 2009; 45.
  5. de Angelis R., Sant M., Coleman M., Francisci S., Baili P., Pierannunzio D., Trama A., Visser O., Brenner H., Ardanaz E., Bielska-Lasota M., Engholm G., Nennecke A., Siesling S., Berrino F., Capocaccia R., and the EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based study. Lancet Oncol 2014; 15:23–34. doi: 10.1016/S1470–2045(13)70546-1
  6. GLOBOCAN2018: estimated cancer incidence, mortality and prevalence worldwide in 2012 [accessed 03.11.2018]. Available at: http://gco.iarc.fr/today/online-analysis-pie
  7. GLOBOCAN2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [accessed 15.04.2017]. Available at: http://globocan.iarc.fr/Default.aspx
  8. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229–263.
  9. Siegel R. L., Giaquinto A. N., Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74: 12–49.
  10. Welch H. G., Mazer B. L., Adamson A. S. The Rapid Rise in Cutaneous Melanoma Diagnoses. N Engl J Med 2021;384: 72–79.
  11. Merabishvili V. M. Survival of cancer patients. St.Petersburg: KOSTA, 2011. – 330 p. (In Russ.)
  12. Merabishvili V. M. Survival of cancer patients. St.Petersburg: KOSTA, 2011. – 408 p. (In Russ.)
  13. Berezkin DP. The study of survival and individual prognosis in malignant tumors. General oncology. Napalkov NP, ed. L. 1989:608–632 (In Russ.).
  14. Merabishvili V. M. Oncology statistics (traditional methods, new information technologies): a guide for doctors. Part II. – St. Petersburg: LLC “Publishing and printing company „COSTA“», 2011. – 248s. (In Russ.)
  15. Berezkin D. P. Methods of studying the survival of cancer patients. Methodological recommendations. L.1982:24 (In Russ.).
  16. Ivanov O. A., Syharev A. E., Starinskii V. V., Egorov S. N. The method of processing the database of cancer patients (survival rate). Methodological recommendations (97/85). M.1997:23 (In Russ.).
  17. Merabishvili V. M. Oncology statistics (traditional methods, new information technologies): a guide for doctors. Part I. St. Petersburg: LLC “Publishing and printing company „COSTA“», 2011. 221 p. (In Russ.).
  18. Merabishvili V. M. Malignant tumors in the North-West Federal Region of Russia (morbidity, mortality, index accuracy, survival). Express-information. Fifth Issue. Editors: Prof. A. M. Belyaev, Prof. A. M. Shcherbakov. – St.Petersburg: T8 Publishing technologies, 2020. – 236 p. (In Russ.).
  19. Merabishvili V. M. Malignant tumors in the North-West Federal Region of Russia (Morbidity, mortality, prevalence rate, survival). Express-information. Sixth Issue. Manual for doctors / ed. by prof A. M. Belyaev– SPb: T8 Publishing technologies, 2023. – 485 p. (In Russ.).
  20. Rogers H. W., Weinstock M. A., Harris A. R., Hinckley M. R., Feldman S. R., Fleischer A. B., Coldiron B. M. Incidence estimate of nonmelanoma skin cancer in the United States, 2006 // Arch Dermatol. – 2010. – Vol. 146, No. 3. – P. 283–7.
  21. Lomas A., Leonardi-Bee J., Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer // Br J Dermatol. – 2012. – Vol. 166, No. 5. – P. 1069–80.
  22. Jayaraman S. S., Rayhan D. J., Hazany S., Kolodney M. S. Mutational landscape of basal cell carcinomas by whole-exome sequencing // J Invest Dermatol. – 2014. – Vol. 134, No. 1. – P. 213–220.
  23. Kuo K. Y., Batra P., Cho H. G., Li S., Chahal H. S., Rieger K. E., Tang J. Y., Sarin K. Y. Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution // J Am Acad Dermatol. – 2017. – Vol. 77, No. 2. – P. 233–234 e2.
  24. Reifenberger J., Wolter M., Knobbe C. B., Kohler B., Schonicke A., Scharwachter C., Kumar K., Blaschke B., Ruzicka T., Reifenberger G. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas // Br J Dermatol. – 2005. – Vol. 152, No. 1. – P. 43–51.
  25. Kadouch D. J., Leeflang M. M., Elshot Y. S., Longo C., Ulrich M., van der Wal A. C., Wolkerstorfer A., Bekkenk M. W., de Rie M. A. Diagnostic accuracy of confocal microscopy imaging vs. punch biopsy for diagnosing and subtyping basal cell carcinoma // J Eur Acad Dermatol Venereol. – 2017. – Vol. 31, No. 10. – P. 1641–1648.
  26. Lallas A., Argenziano G., Zendri E., Moscarella E., Longo C., Grenzi L., Pellacani G., Zalaudek I. Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring // Expert Rev Anticancer Ther. – 2013. – Vol. 13, No. 5. – P. 541–58.
  27. Rowe D. E., Carroll R. J., Day C. L., Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up // J Dermatol Surg Oncol. – 1989. – Vol. 15, No. 3. – P. 315–28.
  28. Avril M. F., Auperin A., Margulis A., Gerbaulet A., Duvillard P., Benhamou E., Guillaume J. C., Chalon R., Petit J. Y., Sancho-Garnier H., Prade M., Bouzy J., Chassagne D. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study // Br J Cancer. – 1997. – Vol. 76, No. 1. – P. 100–6.
  29. Petit J. Y., Avril M. F., Margulis A., Chassagne D., Gerbaulet A., Duvillard P., Auperin A., Rietjens M. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face // Plast Reconstr Surg. – 2000. – Vol. 105, No. 7. – P. 2544–51.
  30. Kuijpers D. I., Thissen M. R., Berretty P. J., Ideler F. H., Nelemans P. J., Neumann M. H. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma // Dermatol Surg. – 2007. – Vol. 33, No. 5. – P. 579–87.
  31. Bath-Hextall F., Ozolins M., Armstrong S. J., Colver G. B., Perkins W., Miller P. S., Williams H. C., Surgery versus Imiquimod for Nodular Superficial basal cell carcinoma study g. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial // Lancet Oncol. – 2014. – Vol. 15, No. 1. – P. 96–105.
  32. Blixt E., Nelsen D., Stratman E. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone // Dermatol Surg. – 2013. – Vol. 39, No. 5. – P. 719–25.
  33. Mohs F. E. Chemosurgical treatment of cancer of the face; a microscopically controlled method of excision // Arch Derm Syphilol. – 1947. – Vol. 56, No. 2. – P. 143–56.
  34. Mohs F. E. Chemosurgery: a method for the microscopically controlled excision of cancer of the skin and lips // Geriatrics. – 1959. – Vol. 14, No. 2. – P. 78–88.
  35. Alcalay J. The value of mohs surgery for the treatment of nonmelanoma skin cancers // J Cutan Aesthet Surg. – 2012. – Vol. 5, No. 1. – P. 1–2.
  36. Alcalay J. Mohs Mapping in the Cloud: An Innovative Method for Mapping Tissue in Mohs Surgery // J Drugs Dermatol. – 2015. – Vol. 14, No. 10. – P. 1127–30.
  37. Siddiqui F. S., Leavitt A. Mohs Micrographic Surgery Appropriate Use Criteria (AUC) Guidelines // StatPearls. – Treasure Island (FL) ineligible companies. Disclosure: Adam Leavitt declares no relevant financial relationships with ineligible companies., 2024.
  38. Kofler L., Kofler K., Schulz C., Breuninger H., Hafner H. M. Sentinel lymph node biopsy for high-thickness cutaneous squamous cell carcinoma // Arch Dermatol Res. – 2021. – Vol. 313, No. 2. – P. 119–126.
  39. Durham A. B., Lowe L., Malloy K. M., McHugh J. B., Bradford C. R., Chubb H., Johnson T. M., McLean S. A. Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma on the Head and Neck // JAMA Otolaryngol Head Neck Surg. – 2016. – Vol. 142, No. 12. – P. 1171–1176.
  40. Sims J. R., Grotz T. E., Pockaj B. A., Joseph R. W., Foote R. L., Otley C. C., Weaver A. L., Jakub J. W., Price D. L. Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients // Surg Oncol. – 2018. – Vol. 27, No. 1. – P. 11–17.
  41. Allen N. C., Martin A. J., Snaidr V. A., Eggins R., Chong A. H., Fernandez-Penas P., Gin D., Sidhu S., Paddon V. L., Banney L. A., Lim A., Upjohn E., Schaider H., Ganhewa A. D., Nguyen J., McKenzie C. A., Prakash S., McLean C., Lochhead A., Ibbetson J., Dettrick A., Landgren A., Allnutt K. J., Allison C., Davenport R. B., Mumford B. P., Wong B., Stagg B., Tedman A., Gribbin H., Edwards H. A., De Rosa N., Stewart T., Doolan B. J., Kok Y., Simpson K., Low Z. M., Kovitwanichkanont T., Scolyer R. A., Dhillon H. M., Vardy J. L., Chadban S. J., Bowen D. G., Chen A. C., Damian D. L. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients // N Engl J Med. – 2023. – Vol. 388, No. 9. – P. 804–812.
  42. Chen A. C., Martin A. J., Choy B., Fernandez-Penas P., Dalziell R. A., McKenzie C. A., Scolyer R. A., Dhillon H. M., Vardy J. L., Kricker A., St George G., Chinniah N., Halliday G. M., Damian D. L. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention // N Engl J Med. – 2015. – Vol. 373, No. 17. – P. 1618–26.
  43. Newman J. G., Hall M. A., Kurley S. J., Cook R. W., Farberg A. S., Geiger J. L., Koyfman S. A. Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review // Head Neck. – 2021. – Vol. 43, No. 9. – P. 2822–2843.
  44. Bhatia S., Brohl A. S., Brownell I., Chandra S., Dakhil S., Ernstoff M. S., Fecher L. A., Gooley T., Hanna G. J., Hibbert R., Kelly C. M., Kiriluk S. M., Nghiem P., Nguyen V., Pelz N., Poisson A. A., Price K. A.R., Sondak V. K., Thompson J. A., Tykodi S. S. ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372 // Journal of Clinical Oncology. – 2018. – Vol. 36, No. 15_suppl. – P. TPS9605-TPS9605.
  45. Gross N. D., Miller D. M., Khushalani N. I., Divi V., Ruiz E. S., Lipson E. J., Meier F., Su Y. B., Swiecicki P. L., Atlas J., Geiger J. L., Hauschild A., Choe J. H., Hughes B. G.M., Schadendorf D., Patel V. A., Homsi J., Taube J. M., Lim A. M., Ferrarotto R., Kaufman H. L., Seebach F., Lowy I., Yoo S. Y., Mathias M., Fenech K., Han H., Fury M. G., Rischin D. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma // N Engl J Med. – 2022. – Vol. 387, No. 17. – P. 1557–1568.
  46. Alcalay J., Tauber G., Fenig E., Hodak E. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma // J Drugs Dermatol. – 2015. – Vol. 14, No. 3. – P. 219–23.
  47. Grob J. J., Gonzalez R., Basset-Seguin N., Schachter J., Vornicova O., Bauman J. R., Grange F., Meyer N., Piulats J. M., Zhang E., Gumuscu B., Swaby R. F., Hughes B. G. M. KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC) // Journal of Clinical Oncology. – 2019. – Vol. 37, No. 15_suppl. – P. TPS9598-TPS9598.
  48. Munhoz R. R., Nader-Marta G., de Camargo V. P., Queiroz M. M., Cury-Martins J., Ricci H., de Mattos M. R., de Menezes T. A.F., Machado G. U.C., Bertolli E., Barros M., de Souza C. E., Franke F., Ferreira F. O., Feher O., de Castro G., Jr. A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma // Cancer. – 2022. – Vol. 128, No. 24. – P. 4223–4231.
  49. Migden M. R., Rischin D., Schmults C. D., Guminski A., Hauschild A., Lewis K. D., Chung C. H., Hernandez-Aya L., Lim A. M., Chang A. L.S., Rabinowits G., Thai A. A., Dunn L. A., Hughes B. G.M., Khushalani N. I., Modi B., Schadendorf D., Gao B., Seebach F., Li S., Li J., Mathias M., Booth J., Mohan K., Stankevich E., Babiker H. M., Brana I., Gil-Martin M., Homsi J., Johnson M. L., Moreno V., Niu J., Owonikoko T. K., Papadopoulos K. P., Yancopoulos G. D., Lowy I., Fury M. G. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma // N Engl J Med. – 2018. – Vol. 379, No. 4. – P. 341–351.
  50. Migden M. R., Khushalani N. I., Chang A. L.S., Lewis K. D., Schmults C. D., Hernandez-Aya L., Meier F., Schadendorf D., Guminski A., Hauschild A., Wong D. J., Daniels G. A., Berking C., Jankovic V., Stankevich E., Booth J., Li S., Weinreich D. M., Yancopoulos G. D., Lowy I., Fury M. G., Rischin D. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial // Lancet Oncol. – 2020. – Vol. 21, No. 2. – P. 294–305.
  51. Marin-Acevedo J. A., Withycombe B. M., Kim Y., Brohl A. S., Eroglu Z., Markowitz J., Tarhini A. A., Tsai K. Y., Khushalani N. I. Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma // Cancers (Basel). – 2023. – Vol. 15, No. 12.
  52. Cavalieri S., Bergamini C., Alfieri S., Resteghini C., Nuzzolese I., Colombo E., Ottini A., Licitra L. Management of patients with skin adnexal carcinomas // EJC Skin Cancer. – 2023. – Vol. 1. – P. 100006.
  53. Kleibert M., Plachta I., Czarnecka A. M., Spalek M. J., Szumera-Cieckiewicz A., Rutkowski P. Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective // Cancers (Basel). – 2022. – Vol. 14, No. 4.
  54. de Iuliis F., Amoroso l., Taglieri l., Vendittozzi S., Blasi l., Salerno G., Lanza R., Scarpa S. Chemotherapy of Rare Skin Adnexal Tumors: A Review of Literature // Anticancer Research. – 2014. – Vol. 34, No. 10. – P. 5263–5268.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1 with table. Dynamic of survival of patients with malignant tumor of the skin (C44), taking into account the stage of disease. M+F. DB PCR NWFD RF

Download (266KB)
Indexing metadata
3. Fig. 2 with table. Dynamic of 1-year survival of man with malignant tumors of skin (C44) in the NWFD RF. 2000–2009 and 2015–2019

Download (152KB)
Indexing metadata
4. Fig. 3 with table. Dynamic of 1-year survival of woman with malignant tumors of skin (C44) in the NWFD RF. 2000–2009 and 2015–2019

Download (158KB)
Indexing metadata

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».